News

PHEXCOM

Solution BY Communication

Call：+86 021-55807300

Position：Home > News >

With U.S. elections nearing, European pharma giants brace for potential pricing action: analysts

With U.S. presidential and congressional campaignsin full swing, it’s not just Americans anxiously awaitingthe results of the upcoming elections. The races couldaffect European pharma companies in a
2020/9/21
Pfizer leans into gene therapy manufacturing with 'build-buy-partner' strategy

In the bustling cell and gene therapy field, manufacturing is a major hurdle for drugmakers hoping to bring 10 to 20 new products to market each year in the coming decade. Pfizer has invested big mon
2020/9/21
BioNTech, CureVac bag $745M in German funding for COVID-19 vaccine hopefuls

Two German biotechs, BioNTech and CureVac, have been at the cutting edge of the hunt for a COVID-19 vaccine—a time-consuming and costly process. In order to get both over the finish line, the German
2020/9/17
Gilead needs 'heroic' Immunomedics revenues to get a return on $21B deal: analyst

Gilead Sciences has long needed to diversify beyond its core antivirals business, and oncology seemeda wise choice for expansion. But should it be paying $21 billion for Immunomedics? Analysts have s
2020/9/16
Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy is Takeda's next-gen cell
2020/9/16
Novavax adds antigens to COVID-19 production pact with Indian vaccines giant

Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast,
2020/9/15
Gilead splashes out $21B for Immmunomedics, keeping the pedal on new target weeks after AZ-Daiichi deal

If industry watchers were amazed by AstraZeneca putting down up to $6 billion in July for a Daiichi Sankyo experimental TROP-2-directed cancer drug, they are now likely even more in awe of the size o
2020/9/15
Eli Lilly, buoyed by Olumiant's COVID-19 data win, eyes emergency nod from FDA

The pharma industry’s massive pandemic response may have yielded another winner, as Eli Lilly’s Olumiant—combined with Gilead’sremdesivir—improved recovery timein patients hospitalized with COVID-19.
2020/9/14
AbbVie to bring most employees back on site Monday despite COVID-19 concerns: report

As newCOVID-19 new infections and deaths in the U.S. continue to march downward, companies are having to make a difficult choice: Stay at home or back to business as usual? For drugmaker AbbVie, this
2020/9/14
Merck KGaA's MilliporeSigma pumps $65M into new facility for next-generation oncology meds

Merck KGaA's MilliporeSigma unit morethan doubled itsgene therapy manufacturing capacity in April as it set its sights on the future. Now, the German drugmakeris making a big down payment on a new ma
2020/9/11

Excipients